"Beyond surging death tolls and reports of drug resistance, the potential for the swine flu virus to mutate into a virulent and lethal form seems increasingly possible over the course of the two billion infections projected by WHO," stated Aethlon Chairman and CEO, Jim Joyce. "While our primary focus remains the treatment of Hepatitis-C virus (HCV), it is now appropriate and important that we take advantage of the opportunity to validate the capability of our Hemopurifier(R) against infectious H1N1 Swine flu virus," concluded Joyce.

Since the beginning of 2009, the Hemopurifier(R) has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. As a result, Aethlon believes the Hemopurifier(R) is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies. Such data further reinforces the position of the Hemopurifier(R) as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Should H1N1 Swine Flu evolve to be highly virulent and resistant to treatment stockpiles, the Hemopurifier(R) is positioned to become a first-line treatment countermeasure to strengthen the clinical benefit of both established and candidate drug treatments.

www.aethlonmedical